Doctors trial £100 blood test that could transform how NHS detects Alzheimer’s | Alzheimer’s
Doctors have initiated a clinical study of 100 pounds of blood tests for Alzheimer’s disease, hoping to transform the destructive situation in NHS.
More than 1000 patients with suspicion of dementia are taken from memory clinics throughout England to see if the test provides better care for faster and more reliable diagnoses and disease.
Alzheimer, the most common form of dementia, more than half a million people in the UK, but it may take years to diagnose. Only 2% of patients have a gold standard test based on a pet scan or timber hole to detect the distinctive properties of the condition.
Although new drugs such as Lacemab and Hardemab have shown that the disease has slowed down, they have a small effect and have been rejected by the UK’s National Institute of Health and Care Excellence (NICE). Hopes are now riding the second generation Alzheimer’s drugs tested in clinical studies.
Alzheimer’s drugs work in the best way when given in the early stages of the disease before the brain is large, irreversible damage. A simple and effective blood test will allow doctors to quickly identify patients who will benefit the most.
Um We expect a large number of treatments to be published in the next 10 years, so we need to prepare national health care and give the benefits of a correct diagnosis, Prof said Prof Jonathan Schott, a neurologist in London, a neurologist in London.
Alzheimer’s disease depends on the accumulation of two basic proteins called amyloids and tau in the brain. The blood test measures a protein called P-Tau217 reflecting the presence of both. The evidence shows that the test can accurately detect amyloid and tau as much as pet scannings and timber drilling.
Essay hire 1,100 people from various geographical, ethnic and economic pasts and people with other medical problems to ensure that the findings are related to a wide population of England.
Half of those in the study will take the results of the blood test within three months after being evaluated by memory services, and the other half will receive the results after 12 months. Doctors will then assess whether the test results help to accelerate the diagnosis and whether they guide the decisions about the future treatment of patients.
In private laboratories that already use the test, the results can be returned within about two weeks.
He is a senior clinical research assistant at the University College Research Center. “This is not about verifying the accuracy we have done before, Ash Ashvin Keshavan said. “This is about showing that it actually makes a difference in the advanced management of patients.”
Researchers suspect that the trial will take two years to hire. If the results are encouraging, NICE will be presented to NICE for whether the test will be presented during NHS.
The Essay is a part of Blood Biomarker Challenge, a millions of pounds supported by the Alzheimer’s Association, Alzheimer Research UK and the People’s Postal Lottery.
“We know that the drug development pipeline for Alzheimer’s disease is currently developing with new potential treatments,” Alzheimer Research UK Research Director Dr Sheona Scales.
“The sooner we can intervene in these experimental or new potential treatments, the chances of success increases. So science is currently moving fast, there is a rate of change, but we need a diagnosis to accelerate to help us unlock it.”
